Equity
€500,272 ▲ 1.8%
IC PHARMA has made a profit without a break since 2021.
IC PHARMA
Part of the group
8 companies in 3 countries
Lifetime
10 annual accounts with figures on one time axispeak €578,260 (2021)
€434,555▲ 3.5%
lowest -€223,703 (2020)
€128,641▼ 16.3%
peak €500,272 (2025)
€500,272▲ 1.8%
€2.7m▲ 0.7%
peak 3.8 FTE (2022)
2.9 FTE▲ 3.6%
Board2 names since 2019
2 directors and 1 other
Owners
98.92%
Documentsfilings and deeds
28-01-20263 days before the deadline
2025financial year
Investments €45,316
Key points
from the 2025 annual accountsDebts
€2.7m 84% of the balance sheet
Financial debts 26%Suppliers 63%Taxes and wages 1%Other 10%
Investments
€45,316 2.4 × depreciation
Green is investment, beige is depreciation. Machinery stands 32.0% higher than in 2024.
Staff
3 employees on 30-06-2025
In 2025, 2 people joined and 2 left.
Filings
10 annual accounts 3 late
The 2020 accounts came latest: 28 days after the end of the period.
Position in the sector
15.8%
Lower solvency than 83% of companies in wholesale trade. Sector median 43.8% · 3,761 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 4,508 companies had the same profile as IC PHARMA has now. Each dot stands for 12 companies, two years later.
96.8%
were still trading
1.6%
stopped another way
1.4%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 4,508 companies, not a prediction for IC PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, , since 10-10-2019
Director, since 10-10-2019
- 98.92%score equity €1.3m (2025) · 30-06-2025 annual accounts of
Shares in 3 companies, including and
Board & ownershipRecent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0505707124
Registered office moved from Brussels to Tubize
New registered office: rue François Englert 10 à 1480 Tubize · Previous registered office: rue du Congrès 35 à 1000 Bruxelles · General meeting of 07-04-2024 · Gazette deed
First establishment
Rue François Englert 10, Tubize
Registered office moved from Watermael-Boitsfort to Brussels
New registered office: rue du Congrès 35 à 1000 Bruxelles · Previous registered office: Chaussée de la Hulpe 177/20 à 1170 Watermael-Boitsfort · Permanent representative: · General meeting of 20-04-2021 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| IC PHARMA Tubize | €3.2m | €0.4m | 15.8% | 2.9 |
| PRION MEDICAL Willebroek | €2.0m | €0.5m | 52.2% | 2.5 |
| Lansinoh Laboratories Benelux Herentals | €3.1m | €0.9m | 50.9% | 2.9 |
| ULTRAZONIC Zandhoven | €2.1m | €0.3m | 45.9% | 4 |
| SERGE HUGARD MANAGEMENT CONSULTING Mont-Saint-Guibert | €1.7m | €0.7m | 48.1% | 3.9 |
| GOODLIFE PHARMA Chastre | €4.3m | €1.2m | 17.9% | 3.3 |
| ID4CARE Nivelles | €1.7m | €0.4m | 9.7% | 6.3 |
These companies have the same main activity as IC PHARMA: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €1.7m and €4.3m, founded between 2012 and 2015.
Official details
Source: KBO- Status
- Active since 26-11-2014Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 30-06-2024
- Establishment unit
- 2.359.997.6271480 Tubize, since 01-05-2024
- Financial year end
- 30 June
- Peppol
- Reachable since 06-11-2025
Annual accounts to 30-06-2025
- ≈ €2.1mestimated
- €3.2m▲ 0.9%
- Employeeson 30-06-2025
- 3=
- Filing
- Filed on 28-01-2026, 3 days before the end of the filing period
Companies linked to IC PHARMA
Subsidiaries and holdings
- 0.27%
Insights on IC PHARMA
IC PHARMA has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €500,272 and a net result of €128,641.
Equity has been growing by about 13% per year since 2019. Its solvency ranks better than 17% of 3,761 sector peers (NACE 46, financial year 2025).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about IC PHARMA
- What is the company number of IC PHARMA?
- The company number of IC PHARMA is 0505.707.124. The VAT number is the same number with BE in front: BE 0505.707.124.
- Where is IC PHARMA based?
- The registered office is at Rue François Englert 10, 1480 Tubize.Company details
- What does IC PHARMA do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of IC PHARMA?
- IC PHARMA is a private limited company (BV).
- When was IC PHARMA founded?
- IC PHARMA was founded on 26-11-2014.
- Is IC PHARMA still active?
- Yes, IC PHARMA is an active enterprise in the KBO register.
- How many employees does IC PHARMA have?
- IC PHARMA had an average of 2.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does IC PHARMA fall under?
- In its 30-06-2024 annual accounts, IC PHARMA states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of IC PHARMA?
- The turnover in financial year 2025 is ≈ €2.1m. This figure is estimated from the gross margin of €434,555 and 36 comparable companies (NACE 464). It probably lies between €1.6m and €3.1m.
- Is IC PHARMA profitable?
- In financial year 2025, IC PHARMA made a profit of €128,641.
- Where can I find the annual accounts of IC PHARMA?
- IC PHARMA filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of IC PHARMA due?
- IC PHARMA must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.